Dose-dependent constipation with higher doses of quetiapine: A case series

International Clinical Psychopharmacology

Volumn 22, Issue 4, 2007, Pages 244-246

  Raedler, Thomas J ^a   Reimer, Jens ^a   Wiedemann, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Constipation; Quetiapine

Indexed keywords

ANTIDEPRESSANT AGENT; BISACODYL; CLOZAPINE; ESCITALOPRAM; LACTULOSE; OLANZAPINE; QUETIAPINE; REBOXETINE; VENLAFAXINE;

ADULT; AKATHISIA; ARTICLE; AUDITORY HALLUCINATION; CLINICAL ARTICLE; COMPULSION; CONSTIPATION; DELUSION; DEPRESSION; DEPRESSIVE PSYCHOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; HUMAN; MALE; PARANOIA; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SUICIDAL BEHAVIOR; THOUGHT DISORDER;

ADULT; ANTIPSYCHOTIC AGENTS; CONSTIPATION; DEPRESSION; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 34249069813     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32805b71a3     Document Type: Article

References (24)

1. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
2. Cheer SM, Wagstaff AJ (2004). Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 18:173-199.
3. Chengappa KN, Pollock BG, Parepally H, Levine J, Kirshner MA, Brar JS, et al. (2000). Anticholinergic differences among patients receiving standard doses of olanzapine or clozapine. J Clin Psychopharmacol 20:311-316.
4. Chew ML, Mulsant BH, Pollock BG, Lehman MF, Greenspan A, Kirshner MA, et al. (2006). A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 88:63-72.
5. Citrome L, Jaffe A, Levine J, Lindenmayer JP (2005). Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry 66:1512-1516.
6. Citrome L, Stroup TS (2006). Schizophrenia, clinical antipsychotic trials of intervention effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 60:933-940.
7. Dando TM, Keating GM (2005). Quetipine: a review of its use in acute mania and depression associated with bipolar disorder. Drugs 5:2533-2551.
8. Drew L, Herdson P (1997). Clozapine and constipation: a serious issue. Aust NZ J Psychiatry 31:149-150.
9. Freudenreich O, Goff DC (2000). Colon perforation and peritonitis associated with clozapine. J Clin Psychiatry 61:950-951.
10. Gefvert O, Lundberg T, Wieselgren IM, Bergström M, Langström B, Wiesel F, et al. (2001). D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 11:105-110.
11. Hayes G, Gibler B (1995). Clozapine-induced constipation. Am J Psychiatry 152:298.
12. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000). A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57: 553-559.
13. Levin TT, Barrett J, Mendelowitz A (2002). Death from clozapine-induced constipation: case report and literature review. Psychosomatics 43:71-73.
14. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
15. McCarthy RH, Terkelsen KG (1994). Esophageal dysfunction in two patients after clozapine treatment. J Clin Psychopharmacol 14:281-283.
16. Nemeroff CB, Kinkead B, Goldstein J (2002). Quetiapine: preclinical studies, pharmacokinetics, drug interactions and dosing. J Clin Psychiatry 63 (13, Suppl):5-11.
17. Pajonk FG, Schwertner AK, Seelig MA (2006). Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series. J Psychopharmacol 20:119-124.
18. Pierre JM, Wirshing DA, Wirshing WC, Rivard JM, Marks R, Mendenhall J, et al. (2005). High-dose quetiapine in treatment refractory schizophrenia. Schizophr Res 73:373-375.
19. Remick RA (1988). Anticholinergic side effects of tricyclic antidepressants and their management. Prog Neuropsychopharmacol Biol Psychiatry 12: 225-232.
20. Saller CF, Salama AI (1993). Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berlin) 112:285-292.
21. Sattar SP, Bhatia SC, Petty F (2004). Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 29:452-457.
22. Schwartz BJ, Frisolone JA (1993). A case report of clozapine-induced gastric outlet obstruction. Am J Psychiatry 150:1563.
23. Théret L, Germain ML, Burde A (1995). Current aspects of the use of clozapine in the Chalons-sur-Marne Psychiatric Hospital: intestinal occlusion with clozapine. Ann Med Psychol (Paris) 153:474-477.
24. Villeneuve E, Lemelin S (2005). Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 66:1298-1303